Mohammad Jad Moussa/X
Nov 15, 2024, 17:40
Mohammad Jad Moussa: Original Series on ICIs in aUA and aNUA of the Urinary Tract at SITC2024
Mohammad Jad Moussa, Oncology Fellow at MD Anderson Cancer Center, shared a post on X:
“SITC2024 GUsm: Original Series on ICIs in Advanced Urachal (aUA) and Non-Urachal Adenocarcinomas (aNUA) of the Urinary Tract – Omar Alhalabi, Matt Campbell, MD Anderson Cancer Center.
- n=22; chemo-exposed (91%), visceral mets (UA: lung ++ peritoneum +/ NUA: lung ++ bone +), 71% single-agent ICI, 29% nivo/ipi
- Limited ICI efficacy (ORR 14.3%, mPFS 4.9 mo) in aUA (n=14), genetic signatures ~ colorectal adeno (TP53, KRAS, GNAS, SMAD4)
- Same pattern in aNUA (smaller cohort, ORR 12.5%, mPFS 2.4 mo), genetically ~ to urothelial ca (TP53, RB1)
- 2 of 3 responses with nivo/ipi -> role of ICI combination or CTLA-4i?
Larger cohorts needed.”
More posts featuring Mohammad Jad Moussa.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 15, 2024, 17:47
Nov 15, 2024, 17:45
Nov 15, 2024, 16:49
Nov 15, 2024, 16:48
Nov 15, 2024, 16:44
Nov 15, 2024, 16:42
Nov 15, 2024, 16:41
Nov 15, 2024, 16:34